Blood cancers are often driven by large-scale genomic rearrangements, including translocations, deletions, duplications, and other structural and copy number changes, that no single assay captures well. In practice, characterizing a hematologic malignancy can mean piecing together results from karyotyping, fluorescence in situ hybridization (FISH), chromosomal microarray, and sequencing, each with its own resolution limits and blind spots.
Nabsys is positioning its Electronic Genome Mapping (EGM) technology as one way to close some of those gaps. At the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20–24 in Montréal, the Providence, RI-based company shared preliminary data on EGM in hematologic malignancies and previewed analysis software built for that application.
Bridging two disciplines
In a Nabsys-sponsored CoLab session on October 22, Alka Chaubey, PhD, FACMG, the company’s chief medical and genomics officer, presented “Electronic Genome Mapping in Hematologic Malignancies: Bridging Cytogenetics and Molecular Genomics” on behalf of Brynn Levy, MSc(Med), PhD, FACMG, of Columbia University. The talk covered early findings on how well EGM detects structural and copy number variants, including how its results compared with established cytogenetic methods.
The work builds on OhmX Platform installations at Columbia University Medical Center, awarded through the RAMP UP Program from Hitachi High-Tech America and Nabsys. Running on OhmX, EGM is designed to give a high-resolution, genome-wide view of structural and copy number variation. Nabsys frames the technology as a complement to existing tools rather than a replacement.
“Researchers need a more complete view of the complex genomic changes in hematologic cancers,” said Barrett Bready, MD, Nabsys’s founder and CEO. “These preliminary findings highlight EGM’s potential to complement established methods.”
Software shaped by users
Alongside the data, Nabsys demonstrated Nabsys Navigator™, its cloud-based platform for EGM analysis and visualization. Navigator includes two pipelines: SV-Discover™, for genome-wide structural variant analysis, and SV-Verify™, for confirming structural variants flagged by other technologies. Booth visitors could also preview the company’s forthcoming hematologic malignancy analysis software, the same tool used to analyze samples in Chaubey’s presentation, and weigh in on its development. Bready said the company is “pairing that work with software development shaped directly by the researchers who will use it.” The OhmX Platform is for research use only and is not intended for diagnostic procedures.